Nimbus Therapeutics

Company profile

About Nimbus Therapeutics

Nimbus Therapeutics is a structure-based drug discovery company that develops breakthrough small molecule medicines through AI-enhanced computational chemistry. Founded in 2009 as Nimbus Discovery and evolving into Nimbus Therapeutics in 2015, the company has established a remarkable track record in precision drug design. Nimbus pursues well-validated but difficult-to-drug targets with high potential to transform patients' lives, combining leading-edge computational technologies with machine learning-based predictive modeling approaches. The company's mission centers on developing breakthrough medicines for patients through precision small molecule design, with exquisite selectivity at the core of everything they do. Nimbus has successfully advanced four programs into clinical development and executed transformative partnerships, including a $6 billion sale of its TYK2 program to Takeda and a $1.2 billion sale of its NASH (ACC) program to Gilead, returning over $4 billion to investors. Nimbus's current pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2 clinical development for microsatellite instability high (MSI-H) tumors, a salt-inducible kinase 2 (SIK2) inhibitor program advancing toward first-in-human studies for inflammatory and autoimmune diseases, and multiple preclinical programs in oncology, immunology, and metabolic diseases. The company is headquartered in Boston, Massachusetts, and prides itself on its nimbleness, expertise, focus on collaboration, and rich supportive culture.

Company description · Nimbus Therapeutics official website